Gene Solutions, a biotech company in Asia with proprietary research and CAP-accredited laboratories in Singapore and Vietnam, unveiled a groundbreaking blood test, SPOTMAS, designed to enhance early lung cancer detection through advanced artificial intelligence (AI) and genomics.
This innovative test, announced at the “Personalised Cancer Care in Asia: Advancing Genomics & AI” event in Singapore, aims to address the significant lung cancer burden in Asia, where 63% of new cases and 62% of deaths occur globally.
SPOTMAS leverages circulating tumour DNA (ctDNA) technology to detect cancer indicators in the blood, offering a non-invasive and affordable alternative to traditional low-dose CT scans. These scans, typically recommended for high-risk populations like heavy smokers, often miss over 50% of lung cancer cases in non-smokers, who account for a significant portion of diagnoses in Southeast Asia. The SPOTMAS Lung test has demonstrated remarkable effectiveness, achieving 90% sensitivity and 92% specificity.
Dr Nguyen Hoai Nghia, Founder of Gene Solutions, highlighted the transformative potential of this technology, stating, “By harnessing the power of ctDNA and AI, we aim to make blood-based cancer screening tests more accurate and more affordable.”
Gene Solutions plans to integrate SPOTMAS into clinical practice across Asia by early 2025, potentially increasing early detection rates and reducing mortality associated with late-stage diagnoses. The company collaborates with over 4,500 healthcare providers in Southeast Asia and has conducted extensive research to support its innovative cancer detection solutions. This initiative marks a significant step forward in making lung cancer screening more accessible and effective for underserved populations.
